{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:49:23Z","timestamp":1790092163277,"version":"4.0.1"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:00:00Z","timestamp":1761609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pediatric acute myeloid leukemia (AML) accounts for approximately 25% of childhood hematologic malignancies. Outcomes have markedly improved, especially in low-risk and intermediate-risk patients, with overall survival (OS) rates approaching 80\u201385%. Prognosis is primarily determined by cytogenetic\/molecular risk and minimal residual disease (MRD) status following induction therapy. While complete remission (CR) traditionally requires morphologic clearance of leukemia with full hematologic recovery, some patients achieve morphologic remission with incomplete recovery (CRi). Although adult studies associate CRi with poor prognosis, its relevance in MRD-negative pediatric AML remains unclear. This study evaluates the prognostic significance of hematologic recovery in MRD-negative, low\/intermediate-risk pediatric AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 120 pediatric AML patients treated at CCHE-57357 between 2012 and 2020 who achieved MRD negativity (&amp;lt;0.1% by 8\u201310 color flow cytometry) after Induction I. Risk stratification followed WHO\/ELN guidelines. For exploratory purposes, intermediate-risk patients with MRD &amp;lt;0.1% were reclassified as \u201cMRD-defined low risk.\u201d Patients were categorized by hematologic recovery: CR (ANC \u22651000\/\u00b5L, platelets \u2265100,000\/\u00b5L), partial hematological recovery (CRh) (ANC \u2265500\/\u00b5L and\/or platelets \u226550,000\/\u00b5L), and CRi (ANC 500\/\u00b5L and\/or platelets &amp;lt;50,000\/\u00b5L). Outcomes included OS, relapse-free survival (RFS), and event-free survival (EFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 120 patients (median age 8.5 years), 25 (21%) achieved CR, 17 (14.3%) CRh, and 78 (64.7%) CRi. CRi patients had numerically lower 5-year OS (63.3%) compared to CRh (76%) and CR (71.8%), though differences were not statistically significant. Platelet recovery alone (complete Platelet recovery (CRp) vs incomplete platelet recovery (CRip) showed a trend toward prognostic relevance (5-year OS: 73.3% vs 57.1%), also non-significant. Infectious complications were common: six sepsis-related deaths occurred in the low-risk group and four in the standard-risk group, with ICU admissions disproportionately higher in standard-risk patients (12 vs 1). CRi patients experienced longer hospital stays and required more transfusion support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In MRD-negative pediatric AML, incomplete hematologic recovery did not significantly predict inferior survival, though trends suggest potential prognostic value\u2014particularly in low-risk patients. CRi may reflect treatment-related toxicity or infectious complications rather than residual disease. These findings support a more nuanced interpretation of remission depth and highlight the need for larger, multi-institutional studies incorporating molecular risk refinement and clinical context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1661036","type":"journal-article","created":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:17:59Z","timestamp":1761628679000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The prognostic significance of incomplete hematological recovery in pediatric patients with low\/intermediate risk AML and negative MRD after induction 1"],"prefix":"10.3389","volume":"15","author":[{"given":"Nessma M.","family":"Shahin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanafy","family":"Hafez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherine","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahla","family":"El-Sharkawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Elnashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"El-Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/NM.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/MOP.0000000000000855","article-title":"Pediatric acute myeloid leukemia: updates on biology, risk stratification, and therapy","volume":"32","author":"Elgarten","year":"2020","journal-title":"Curr Opin Pediatr"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02143-8","article-title":"Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts","volume":"38","author":"Appelbaum","year":"2024","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3518","article-title":"Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia","volume":"33","author":"Chen","year":"2015","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3324\/haematol.2022.281106","article-title":"Relapsed pediatric acute myeloid leukaemia: state-of-the- art in 2023","volume":"108","author":"Egan","year":"2023","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01692-0","article-title":"Association of hematologic response and assay sensitivity on the prognostic impact of measurable residual disease in acute myeloid leukemia: a systematic review and meta-analysis","volume":"36","author":"Short","year":"2022","journal-title":"Leukemia"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood J Am Soc Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000676","article-title":"Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the european leukemiaNet MRD working party","volume":"6","author":"Tettero","year":"2021","journal-title":"HemaSphere"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.10515","article-title":"Four versus five chemotherapy courses in patients with low risk acute myeloid leukemia: A Children\u2019s Oncology Group report","author":"Getz","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023313","article-title":"Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia","volume":"144","author":"Le","year":"2024","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/cancers14030616","article-title":"Blood count recovery following induction therapy for acute myeloid leukemia in children does not predict survival","volume":"14","author":"Pommert","year":"2022","journal-title":"Cancers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"100806","DOI":"10.1016\/j.blre.2021.100806","article-title":"The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses","volume":"48","author":"Shallis","year":"2021","journal-title":"Blood Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1190969","article-title":"Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia","volume":"58","author":"Yamazaki","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4274\/tjh.galenos.2019.2019.0154","article-title":"The impact of early versus late platelet and neutrophil recovery after induction chemotherapy on survival outcomes of patients with acute myeloid leukemia","volume":"37","author":"\u00c7ift\u00e7iler","year":"2020","journal-title":"Turkish J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01261-6","article-title":"Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation","volume":"56","author":"Percival","year":"2021","journal-title":"Bone marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.1066","article-title":"Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group and M. D. Anderson Cancer Center Study","volume":"28","author":"Walter","year":"2010","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009391","article-title":"Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity","volume":"7","author":"Bazinet","year":"2023","journal-title":"Blood Adv"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27231","article-title":"Associations between neutrophil recovery time, infections and relapse in pediatric acute myeloid leukemia","volume":"65","author":"L\u00f8hmann","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1200\/JCO.18.00313","article-title":"Occurrence of treatment-related cardiotoxicity and its impact on outcomes among children treated in the AAML0531 clinical trial: A report from the children\u2019s oncology group","volume":"37","author":"Getz","year":"2019","journal-title":"JCO"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1661036\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:18:00Z","timestamp":1761628680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1661036\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,28]]},"references-count":20,"alternative-id":["10.3389\/fonc.2025.1661036"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1661036","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,28]]},"article-number":"1661036"}}